BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3209626)

  • 1. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
    Bayer AJ; Day JJ; Finucane P; Pathy MS
    J Clin Pharm Ther; 1988 Jun; 13(3):191-4. PubMed ID: 3209626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
    Crevoisier C; Hoevels B; Zürcher G; Da Prada M
    Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
    Nyholm D; Lewander T; Gomes-Trolin C; Bäckström T; Panagiotidis G; Ehrnebo M; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2012; 35(3):111-7. PubMed ID: 22549097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
    Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
    Gasser UE; Crevoisier C; Ouwerkerk M; Lankhaar G; Dingemanse J
    Eur J Pharm Biopharm; 1998 Sep; 46(2):223-8. PubMed ID: 9795070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
    Malcolm SL; Allen JG; Bird H; Quinn NP; Marion MH; Marsden CD; O'Leary CG
    Eur Neurol; 1987; 27 Suppl 1():28-35. PubMed ID: 3428307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
    Gasser UE; Fischer A; Timmermans JP; Arnet I
    BMC Pharmacol Toxicol; 2013 Apr; 14():24. PubMed ID: 23617953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrodynamically balanced system: a novel principle of controlled drug release.
    Erni W; Held K
    Eur Neurol; 1987; 27 Suppl 1():21-7. PubMed ID: 3322836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Ghika J; Gachoud JP; Gasser U
    Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
    César Ida C; Byrro RM; Cardoso FF; Mundim IM; Teixeira Lde S; da Silva EP; Gomes SA; Bonfim RR; Pianetti GA
    J Pharm Biomed Anal; 2011 Dec; 56(5):1094-100. PubMed ID: 21856105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
    Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
    AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP; Marion MH; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.